Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients
Top Cited Papers
- 28 April 2021
- journal article
- letter
- Published by Elsevier BV in Annals of Oncology
- Vol. 32 (8), 1051-1053
- https://doi.org/10.1016/j.annonc.2021.04.020
Abstract
No abstract availableFunding Information
- Roche
- Gilead Sciences
- Bristol-Myers Squibb
- Pfizer
- Merck Sharp and Dohme
This publication has 4 references indexed in Scilit:
- Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant RecipientsJAMA, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- COVID-19 and Cancer: a Comprehensive ReviewCurrent Oncology Reports, 2020